BPTSY (Biophytis) OCF Margin %: 0.00% (As of Jun. 2025)


BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis OCF Margin %?

Biophytis BPTSY 18 OCF Margin % is 0.00% as of Jun. 2025. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Biophytis ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Biophytis's Cash Flow from Operations for the six months ended in Jun. 2025 was $-4.26 Mil. Biophytis's Revenue for the six months ended in Jun. 2025 was $0.00 Mil. Therefore, Biophytis's OCF Margin % for the quarter that ended in Jun. 2025 was 0.00%.

As of today, Biophytis's current OCF Yield % is -348.47%.

The historical rank and industry rank for Biophytis's OCF Margin % or its related term are showing as below:


BPTSY's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Biophytis OCF Margin % Related Terms

Biophytis OCF Margin % Historical Data

* Premium members only.

The historical data trend for Biophytis's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis OCF Margin % Chart

Biophytis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biophytis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BPTSY
18GF Score
Biophytis SA BPTSY
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Biophytis's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-9.05/0
= %

Biophytis's OCF Margin for the quarter that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-4.258/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Biophytis (BPTSY) has a OCF Margin % of 0.00% as of Jun. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biophytis and its competitors. According to the industry distribution chart, Biophytis ranks #999999 out of 959 companies in the Biotechnology industry.
Is Biophytis' OCF Margin % too high?
Biophytis' current OCF Margin % is 0.00%. Based on the distribution chart, Biophytis ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biophytis ranks #999999 out of 959 companies for OCF Margin %. This places Biophytis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biophytis and its competitors. Biophytis's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biophytis (BPTSY), the current OCF Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price